Can-Fite BioPharma American Depositary Shares
CANF
12 hedge funds and large institutions have $2.43M invested in Can-Fite BioPharma American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
132% more capital invested
Capital invested by funds: $1.05M → $2.43M (+$1.38M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
9% more funds holding
Funds holding: 11 → 12 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.72M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$226K |
| 3 |
Renaissance Technologies
New York
|
+$184K |
| 4 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$59K |
| 5 |
Morgan Stanley
New York
|
+$23.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
-$91K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$88K |
| 3 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$52.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$23K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $1.45M | +$1.72M | +4,375 | New |
|
|
2
Morgan Stanley
New York
| $326K | +$23.2K | +59 | +6% |
|
|
CAN
3
Cetera Advisor Networks
El Segundo,
California
| $217K | -$52.3K | -133 | -17% |
|
|
4
Acadian Asset Management
Boston,
Massachusetts
| $189K | +$226K | +574 | New |
|
|
5
Renaissance Technologies
New York
| $155K | +$184K | +467 | New |
|
|
6
Fifth Third Bancorp
Cincinnati,
Ohio
| $50K | +$59K | +150 | New |
|
7
Stifel Financial
St. Louis,
Missouri
| $20K | – | – | – |
|
8
Citigroup
New York
| $9K | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
10
Osaic Holdings
Scottsdale,
Arizona
| $2K | +$2.36K | +6 | New |
|
|
APA
11
American Portfolios Advisors
Holbrook,
New York
| $1.83K | – | – | – |
|
|
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $885 | – | – | – |
|
|
SG
13
StoneX Group
New York
| – | -$91K | -200 | Closed |
|
|
14
Citadel Advisors
Miami,
Florida
| – | -$88K | -193 | Closed |
|
|
TSS
15
Two Sigma Securities
New York
| – | -$23K | -51 | Closed |
|
|
16
UBS Group
Zurich,
Switzerland
| – | -$18K | -39 | Closed |
|
CANF Hedge Fund Activity: Q3 2021 in Review
12 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2021, worth a combined $2.43M — up 132% from $1.05M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CANF positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.72M. The largest seller was StoneX Group, exiting entirely with an estimated $91K sold.
- 12 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2021, up from 11 in Q2 2021.
- Funds reported $2.43M of Can-Fite BioPharma American Depositary Shares stock for Q3 2021, up 132% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2021 and 4 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2021 was Armistice Capital, an estimated $1.72M added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2021 was StoneX Group, an estimated $91K sold.
Based on aggregated 13F filings for Q3 2021.